| Protocol Number |
Title |
2003NT047
|
CALGB 140202: The CALGB Lung Cancer Tissue Bank |
2003NT056
|
Methods for Tobacco Exposure Reduction in Human - Study 2: Comparisons of Nicotine-Free Cigarettes, Extra Low Nicotine Cigarette vs. Medicinal Nicotine; Part of Hatsukami's Tobacco Exposure Reduction |
2005LS068
|
Phase I Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies |
2005LS083
|
Phase II Clinical Study of Weekly Topotecan in Combination with Bevacizumab in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Prior Systemic Chemotherapy |
2007CG023
|
MT2006-25: CTN 0403 - A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Cell Transplantation |
2007CG081
|
ECOG 1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely resected Stage 1B (>/= 4 cm) - Non- Small Cell Lung Cancer. |
2007CG083
|
CALGB 140503: Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (<2 cm) Peripheral Non-Small Cell Lung Cancer |
2007IS056
|
A double-blind, randomized, placebo-controlled phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-positive Non-Small Cell Lung Cancer (GSK 109493) |
2007IS134
|
Registration Phase III Study of Lucanix (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy (NovaRx NR001-03) |
2007NT127
|
Randomized Trial of PEITC as a Modifier of NNK Metabolism in Smokers |
2007NT129
|
Oral Tobacco as Harm Reduction Method for Smokers: Study 1: Preference, Health Effects and Efficacy of Four Oral Tobacco Products for Smoking Cessation |
2008CG076
|
CALGB 30504: Combination Chemotherapy With or Without Maintainence Sunitinib Malate (IND 74019; NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A phase IB/Randomized Phase II study |
2008CG102
|
CALGB 30704 A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC#736511, IND#74019) or Pemetrexed Plus Sunitinib in the Second-line Treatment of Advanced Non-small Cell Lung Cancer |
2008CG157
|
COG AREN0533 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors |
2008IS026
|
A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients with Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy (Pharmion: AMR-PH-GL-2007-CL-001) |
2008IS090
|
H3E-MC-JMIG: Phase III Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology |
2008LS043
|
Phase II Trial of Bortezomib and Rituximab for Patients with Post Transplant Lymphoproliferative Disorders (PTLD) MT2008-05R |
2008NT001
|
Biomarker Feedback for Smoking Cessation |
2008NT003
|
Improving NRT Adherence and Outcomes in Homeless Smokers |
2008NTLS109
|
Clinical Response to Biomarker Documentation of Child Secondhand Smoke Exposure |
2009CG061
|
CALGB 30506 A Randomized Phase III Trial of Adjuvant Therapy in Earlystage Non-Small Cell Lung Cancer Evaluating the Potential Utility of a Genomic Prognostic Model to Identify Patients as Candidates for Adjuvant Chemotherapy |
Clinical Trials Help